SK282524B6 - Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu - Google Patents

Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu Download PDF

Info

Publication number
SK282524B6
SK282524B6 SK101-95A SK10195A SK282524B6 SK 282524 B6 SK282524 B6 SK 282524B6 SK 10195 A SK10195 A SK 10195A SK 282524 B6 SK282524 B6 SK 282524B6
Authority
SK
Slovakia
Prior art keywords
methoxy
preparation
optically pure
methyl
sulfinyl
Prior art date
Application number
SK101-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK10195A3 (en
Inventor
Per Lennart Lindberg
Unge Sverker Von
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282524(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK10195A3 publication Critical patent/SK10195A3/sk
Publication of SK282524B6 publication Critical patent/SK282524B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
SK101-95A 1993-05-28 1994-05-27 Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu SK282524B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds
PCT/SE1994/000509 WO1994027988A1 (fr) 1993-05-28 1994-05-27 Sels optiquement purs de composes de pyridinylmethyle sylfinyl-ih-benzimidazole

Publications (2)

Publication Number Publication Date
SK10195A3 SK10195A3 (en) 1995-09-13
SK282524B6 true SK282524B6 (sk) 2002-10-08

Family

ID=20390088

Family Applications (1)

Application Number Title Priority Date Filing Date
SK101-95A SK282524B6 (sk) 1993-05-28 1994-05-27 Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu

Country Status (42)

Country Link
US (5) US5693818A (fr)
EP (3) EP1020460B1 (fr)
JP (3) JP3549111B2 (fr)
KR (1) KR100337274B1 (fr)
CN (2) CN1055469C (fr)
AT (1) ATE197452T1 (fr)
CA (2) CA2139653C (fr)
CL (1) CL2009000805A1 (fr)
CY (1) CY2224B1 (fr)
CZ (1) CZ287876B6 (fr)
DE (4) DE69435220D1 (fr)
DK (3) DK0652872T3 (fr)
DZ (1) DZ1785A1 (fr)
EE (1) EE03157B1 (fr)
ES (3) ES2326404T3 (fr)
FI (2) FI117755B (fr)
GR (2) GR970300012T1 (fr)
HR (1) HRP940307B1 (fr)
HU (1) HU226824B1 (fr)
IL (1) IL109684A (fr)
IS (1) IS1854B (fr)
LT (1) LT3287B (fr)
LU (1) LU91870I2 (fr)
LV (1) LV11034B (fr)
MA (1) MA23210A1 (fr)
MY (1) MY121192A (fr)
NO (2) NO307378B1 (fr)
NZ (1) NZ266915A (fr)
PL (1) PL178994B1 (fr)
PT (3) PT652872E (fr)
RU (1) RU2137766C1 (fr)
SA (2) SA94140756B1 (fr)
SE (1) SE9301830D0 (fr)
SG (1) SG49283A1 (fr)
SI (2) SI9420002B (fr)
SK (1) SK282524B6 (fr)
TN (1) TNSN94058A1 (fr)
TW (1) TW389761B (fr)
UA (1) UA60289C2 (fr)
WO (1) WO1994027988A1 (fr)
YU (1) YU49065B (fr)
ZA (1) ZA943557B (fr)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
EE03305B1 (et) 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
CA2298823C (fr) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Composition stabilisee comprenant un compose de type benzimidazole
NZ510180A (en) 1998-08-10 2002-11-26 Univ California Prodrugs of the pyridyl-methylsulphonyl-benzimidazole type proton pump inhibitors
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
ATE271556T1 (de) 1998-11-18 2004-08-15 Astrazeneca Ab Verbesserter chemischer prozess und eine pharmazeutische zubereitung
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
WO2000076556A2 (fr) * 1999-06-11 2000-12-21 Neorx Corporation Complexe a forte dose de radionucleides destine a la suppression de la moelle osseuse
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
DE60023154T2 (de) * 1999-08-26 2006-06-22 Aaipharma Inc. Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
EP1595879A3 (fr) * 1999-08-26 2010-01-27 aaiPharma Inc. Composés de benzimidazole substitués par un alkoxy, préparations pharmaceutiques contenant ces derniers, et procédés d'utilisation
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CA2386277A1 (fr) * 1999-10-01 2001-04-12 Natco Pharma Limited Composition pharmaceutique amelioree et procede de fabrication
MXPA02003762A (es) * 1999-10-20 2002-09-30 Eisai Co Ltd Metodos para estabilizar compuestos basados en benzimidazol.
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
WO2001062248A1 (fr) 2000-02-24 2001-08-30 Kopran Research Laboratories Limited Derives de benzimidazole antiulcereux a acidite stable administrables oralement
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030212274A1 (en) * 2000-05-15 2003-11-13 Bakthavathsalan Vijayaraghavan Novel amorphous form of omeprazole salts
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
JP5412023B2 (ja) 2000-08-04 2014-02-12 武田薬品工業株式会社 ベンズイミダゾール化合物の塩およびその用途
CA2386716C (fr) * 2002-05-17 2012-07-24 Bernard Charles Sherman Sel de magnesium de s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
EP1390081A2 (fr) 2001-01-08 2004-02-25 Neorx Corporation Composes, compositions et methodes therapeutiques et diagnostiques
WO2002083608A2 (fr) * 2001-04-13 2002-10-24 Apsinterm Llc Procedes de preparation de sulfinamides et de sulfoxydes
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US6884810B2 (en) 2001-09-18 2005-04-26 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
ES2286408T3 (es) 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
DE60304726T2 (de) * 2002-07-19 2007-08-09 Winston Pharmaceuticals Llc, Newport Beach Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004012659A2 (fr) * 2002-08-01 2004-02-12 Nitromed, Inc. Inhibiteurs nitroses de la pompe a protons, compositions et procedes d'utilisation
EP1546131A1 (fr) 2002-08-30 2005-06-29 Dr. Reddy's Laboratories Ltd. Hydrates amorphes d'esomeprazole magnesium et leur procede de preparation
EP2596791B1 (fr) 2002-10-16 2015-04-01 Takeda Pharmaceutical Company Limited Préparations solides stables
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
BR0315574A (pt) 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
WO2004046134A2 (fr) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Composes d'esomeprazole cristallins et procede permettant de preparer ces composes
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
ES2397380T3 (es) 2002-12-06 2013-03-06 Takeda Gmbh Procedimiento para preparar compuestos activos ópticamente puros
ES2383679T3 (es) 2002-12-06 2012-06-25 Nycomed Gmbh Procedimiento para la preparación de (S)-pantoprazol
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
WO2004066924A2 (fr) * 2003-01-24 2004-08-12 Andrx Labs Llc Nouvelle formulation pharmaceutique contenant un inhibiteur de pompe a proton et un antiacide
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
BRPI0407906A (pt) * 2003-02-28 2006-02-14 Ranbaxy Lab Ltd polimorfos de s-omeprazol
WO2004089935A1 (fr) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Nouvelles formes cristallines de s-omeprazole magnesium
WO2004099182A1 (fr) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Sel de zinc de (s)-omeprazole
EP1633736A1 (fr) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Sel de baryum d'un derive de benzimidazole
BRPI0412590A (pt) * 2003-07-15 2006-09-19 Allergan Inc processo para preparação de pró-drogas isomericamente puras de inibidores de bomba de próton
CA2531564C (fr) * 2003-07-18 2016-01-19 Santarus, Inc. Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe
WO2005007117A2 (fr) * 2003-07-18 2005-01-27 Santarus, Inc. Formulation pharmaceutique et procede de traitement de troubles gastro-intestinaux lies a l'acidite
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
ATE386522T1 (de) * 2003-07-23 2008-03-15 Nycomed Gmbh Alkalisalze von protonenpumpen-hemmern
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
CA2540105A1 (fr) * 2003-09-25 2005-03-31 Natco Pharma Limited Capsule en gelatine souple enterique contenant de l'esomeprzole et procede de preparation associe
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005034924A1 (fr) * 2003-10-14 2005-04-21 Natco Pharma Limited Pastilles a enrobage enterique comprenant de l'esomeprazole, capsule de gelatine dure renfermant celles-ci et procede de preparation associe
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (fr) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Procede de preparation d'un sel magnesique d'omeprazole
EP1740571B1 (fr) 2004-04-28 2009-07-29 Hetero Drugs Limited Methode servant a preparer des composes de pyridinylmethyl-1h-benzimidazole sous forme d'enantiomeres simples ou enrichis
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
ATE456566T1 (de) * 2004-05-28 2010-02-15 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
US20080249134A1 (en) * 2004-06-24 2008-10-09 Ursula Hohlneicher New Esomeprazole Sodium Salt Crystal Modification
CN103121992A (zh) * 2004-06-24 2013-05-29 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
AU2005268056B2 (en) 2004-08-06 2008-07-31 Eisai R&D Management Co., Ltd. Salts of benzimidazole derivative with amines and process for production thereof
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
EP1830822A1 (fr) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Composition pharmaceutique stable comprenant un substance active sous la forme d'une solution solide
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
WO2006099810A1 (fr) 2005-03-25 2006-09-28 Livzon Pharmaceutical Group Inc. Dérivés de sulfoxyde substitués, méthodes de synthèse desdits dérivés et applications desdits dérivés
US20090298884A1 (en) * 2005-05-06 2009-12-03 Glenmark Generics Ltd. Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
EP1883405A4 (fr) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A Methodes de traitement de la nephrolithiase
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1891043A1 (fr) * 2005-06-15 2008-02-27 Hetero Drugs Limited Ésoméprazole hydraté amorphe
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
JP5242393B2 (ja) * 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 高血圧症の治療方法
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (fr) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Formes polymorphiques de sels de magnesium de (s)-omeprazole et procedes de preparation desdites formes
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
WO2007067128A1 (fr) 2005-12-05 2007-06-14 Astrazeneca Ab Nouveau procede de fabrication d’esomeprazole sous forme non saline
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
ATE428707T1 (de) 2005-12-28 2009-05-15 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
AR056062A1 (es) * 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
ES2355164T3 (es) * 2006-06-07 2011-03-23 Astrazeneca Ab Nuevo método para la preparación de sales de amonio de esomeprazol.
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
WO2008004245A1 (fr) 2006-07-05 2008-01-10 Lupin Limited Procédé pour la préparation d'énantiomères optiquement purs ou optiquement enrichis de composés sulfoxydes
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008067037A2 (fr) 2006-10-05 2008-06-05 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
EP2086543A2 (fr) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
KR20150024919A (ko) * 2006-11-13 2015-03-09 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP1947099A1 (fr) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Procédé pour l'élimination de solvant des sels d'oméprazole
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EA200900985A1 (ru) * 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения оптически чистого омепразола
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2008102145A2 (fr) 2007-02-21 2008-08-28 Cipla Limited Procédé pour la préparation de ésoméprazole magnésium dihydraté
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
RU2341524C1 (ru) * 2007-05-02 2008-12-20 Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН) СПОСОБ ПОЛУЧЕНИЯ ОПТИЧЕСКИ АКТИВНОГО 5-МЕТОКСИ-2-((4-МЕТОКСИ-3,5-ДИМЕТИЛПИРИДИН-2-ИЛ)МЕТИЛСУЛЬФИНИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛА
EP2000468A1 (fr) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Sels d'ésoméprazole et procédés pour leur préparation
US8492551B2 (en) * 2007-06-07 2013-07-23 Aurobindo Pharma. Ltd. Process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
WO2009040825A1 (fr) 2007-09-25 2009-04-02 Hetero Drugs Limited Procédé de préparation d'ésoméprazole pur sur le plan énantiomère
WO2009047775A2 (fr) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphes de sels de l'ésoméprazole
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009145368A1 (fr) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Procédé amélioré de préparation de (s)-oméprazole à partir d'un racémate d'oméprazole à l’aide d'un agent de résolution optique
EP2143722A1 (fr) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
EP2147918A1 (fr) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Procédé de préparation de magnésium d'oméprazole S dans une forme stable
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2264024A1 (fr) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Procédé de préparation d'inhibiteurs de la pompe à protons énantiomériquement enrichis
WO2010058409A2 (fr) 2008-11-18 2010-05-27 Hetero Research Foundation Purification optique d'esoméprazole
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (fr) 2009-02-24 2010-09-02 Cipla Limited Polymorphe de l'ésoméprazole de potassium et sa préparation
EP2445499A4 (fr) 2009-06-25 2013-02-27 Astrazeneca Ab Procede pour le traitement d'un patient a risque de developer un ulcere associe a nsaid
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
EP2319504A1 (fr) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Forme pharmaceutique solide
EP2499125B1 (fr) 2009-11-12 2016-01-27 Hetero Research Foundation Procédé de dédoublement de l'oméprazole
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080501A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2345408A3 (fr) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Formulations de médicament labiles acides
EP2534144B1 (fr) 2010-02-12 2014-09-03 Esteve Química, S.A. Procédé de préparation du sel de sodium d' Esoméprazole
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
CA2812034C (fr) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methodes de traitement simultane a base de theophylline et de febuxostat
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (fr) 2011-11-25 2013-06-06 Mahmut Bilgic Formulation comprenant du benzimidazole
EP2601947A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
EP2790696A1 (fr) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combinaison d'un antagoniste de crth2 et d'un inhibiteur de pompe à protons pour le traitement de l' sophagite à éosinophiles
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
WO2015155307A1 (fr) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de rivaroxaban et d'inhibiteurs de pompe à protons
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (fr) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé efficace pour la préparation d'ésoméprazole (S)-binol complexe
WO2016104668A1 (fr) 2014-12-26 2016-06-30 国立大学法人 東京大学 Procédé de fabrication d'un composé inhibiteur de la pompe à protons ayant une activité optique
EP3064495B1 (fr) 2015-03-06 2016-12-14 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé amélioré pour la préparation de l'esomeprazole optiquement pure
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
WO2018191210A1 (fr) * 2017-04-11 2018-10-18 Mclaughlin Gormley King Company Huile de sévadille et ses utilisations
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
CA3146660A1 (fr) * 2019-07-16 2021-01-21 Kindred Biosciences, Inc. Formulations d'esomeprazole pour equides et leurs procedes d'utilisation
JP7335002B2 (ja) 2019-08-29 2023-08-29 学校法人東京理科大学 スルホキシド化合物のエナンチオマー調製方法及びエナンチオマー調製システム
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (fr) * 1986-02-13 1994-02-15 Tadashi Makino Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) † 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
AU6713194A (en) * 1993-04-27 1994-11-21 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Also Published As

Publication number Publication date
FI950377L (fi) 1995-01-27
JP3959056B2 (ja) 2007-08-15
HK1028044A1 (en) 2001-02-02
ES2326405T5 (es) 2016-02-15
IS1854B (is) 2003-02-21
SI9420002B (sl) 2009-12-31
CL2009000805A1 (es) 2009-08-21
IL109684A (en) 2002-05-23
ES2099047T1 (es) 1997-05-16
DE69435220D1 (de) 2009-09-03
WO1994027988A1 (fr) 1994-12-08
YU49065B (sh) 2003-08-29
AU6902494A (en) 1994-12-20
DK1020460T3 (da) 2009-08-10
PT1020460E (pt) 2009-07-29
LT3287B (en) 1995-06-26
DZ1785A1 (fr) 2002-02-17
JP3549111B2 (ja) 2004-08-04
CA2139653C (fr) 2001-07-10
HU9500247D0 (en) 1995-03-28
HU226824B1 (en) 2009-11-30
EP1020460A2 (fr) 2000-07-19
JP2004043494A (ja) 2004-02-12
SK10195A3 (en) 1995-09-13
CZ20295A3 (en) 1995-10-18
CY2224B1 (en) 2003-04-18
NO2011009I1 (no) 2011-06-20
JP4039999B2 (ja) 2008-01-30
TW389761B (en) 2000-05-11
CN1110477A (zh) 1995-10-18
CA2337581A1 (fr) 1994-12-08
FI20070002A7 (fi) 2007-01-02
CN1107503C (zh) 2003-05-07
SG49283A1 (en) 1998-05-18
FI117755B (fi) 2007-02-15
HRP940307B1 (en) 2001-06-30
TNSN94058A1 (fr) 1995-04-25
GR3035365T3 (en) 2001-05-31
IL109684A0 (en) 1994-12-29
CN1055469C (zh) 2000-08-16
EP1020461A2 (fr) 2000-07-19
SE9301830D0 (sv) 1993-05-28
ES2099047T3 (es) 2001-03-01
NZ266915A (en) 1996-10-28
SA05260103B1 (ar) 2010-01-31
US20100222591A1 (en) 2010-09-02
US20080312449A1 (en) 2008-12-18
EP1020460A3 (fr) 2003-10-15
HK1028045A1 (en) 2001-02-02
DE69426254T2 (de) 2001-06-07
SI9420002A (en) 1995-08-31
RU95105587A (ru) 1996-10-27
US6143771A (en) 2000-11-07
LV11034B (en) 1996-10-20
DE652872T1 (de) 1997-09-04
LU91870I2 (fr) 2011-11-21
NO950263D0 (no) 1995-01-24
HK1008330A1 (en) 1999-05-07
EP1020461A3 (fr) 2006-10-04
CA2139653A1 (fr) 1994-12-08
UA60289C2 (uk) 2003-10-15
DE69435221D1 (de) 2009-09-03
ES2326405T3 (es) 2009-10-09
FI20070002L (fi) 2007-01-02
KR100337274B1 (ko) 2003-12-31
SA94140756B1 (ar) 2006-05-20
YU31494A (sh) 1997-05-28
EP1020461B1 (fr) 2009-07-22
LTIP1941A (en) 1994-12-27
PT1020461E (pt) 2009-07-29
LV11034A (lv) 1996-02-20
CZ287876B6 (cs) 2001-03-14
IS4161A (is) 1994-11-29
JPH07509499A (ja) 1995-10-19
PL178994B1 (pl) 2000-07-31
US5714504A (en) 1998-02-03
GR970300012T1 (en) 1997-05-31
DK1020461T4 (en) 2016-02-15
PT652872E (pt) 2001-04-30
MA23210A1 (fr) 1994-12-31
HRP940307A2 (en) 1996-12-31
EP1020460B1 (fr) 2009-07-22
DE69426254D1 (de) 2000-12-14
HUT71888A (en) 1996-02-28
MY121192A (en) 2006-01-28
SI22752A (sl) 2009-10-31
NO307378B1 (no) 2000-03-27
RU2137766C1 (ru) 1999-09-20
ES2326404T3 (es) 2009-10-09
EP0652872B1 (fr) 2000-11-08
SI22752B (sl) 2010-01-29
KR950702553A (ko) 1995-07-29
NO950263L (no) 1995-01-24
DK1020461T3 (da) 2009-08-10
ATE197452T1 (de) 2000-11-11
EP1020461B2 (fr) 2015-10-21
ZA943557B (en) 1995-04-11
FI950377A0 (fi) 1995-01-27
JP2004043493A (ja) 2004-02-12
AU676337B2 (en) 1997-03-06
CN1259346A (zh) 2000-07-12
US5693818A (en) 1997-12-02
DK0652872T3 (da) 2001-03-05
PL307261A1 (en) 1995-05-15
EP0652872A1 (fr) 1995-05-17
EE03157B1 (et) 1999-02-15

Similar Documents

Publication Publication Date Title
SK282524B6 (sk) Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu
US6875872B1 (en) Compounds
WO1995032959A1 (fr) Nouveaux derives de dialcoxy-pyridinyl-benzimidazole
AU676337C (en) Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds
EP0712400A1 (fr) Nouvelles benzinidazoles substituees
HK1028045B (en) The sodium salt of the (-)-enantiomer of omeprazole
HK1008330B (en) Optically pure magnesium-salt of pyridinylmethyl sulfinyl-1h-benzimidazole compound
SK5896A3 (en) Substituted benzimideazoles
HK1028044B (en) Magnesium salt of the (-)-enantiomer of omeprazole and its use

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: NAPROXEN A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 29/0782/10-S 20101112; FIRST REGISTRATION: GB PL 17901/0263 - 0001 20101105

Spc suppl protection certif: 4-2011

Filing date: 20110510

SPCR Rejection of an spc

Free format text: PRODUCT NAME: NAPROXEN A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 29/0782/10-S 20101112; FIRST REGISTRATION; GB PL 17901/0263 20101105

Spc suppl protection certif: 4-2011

Filing date: 20110510

MG4A Partial revocation of patent

Effective date: 20121212

MK4A Patent expired

Expiry date: 20140527